Waverley Pharma Inc
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.
Waverley Pharma Inc (WAVE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.059x
Based on the latest financial reports, Waverley Pharma Inc (WAVE) has a cash flow conversion efficiency ratio of 0.059x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-138.86K) by net assets (CA$-2.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Waverley Pharma Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Waverley Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Waverley Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Waverley Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Forza Innovations Inc
PINK:FORZ
|
0.003x |
|
SANDY SPRING BANCRP
BE:SD2
|
0.020x |
|
EL Ezz Aldekhela Steel - Alexandria
EGX:IRAX
|
N/A |
|
Florentaise SA
PA:ALFLO
|
0.233x |
|
Nissan
TA:NISA
|
0.039x |
|
Craven House Capital PLC
LSE:CRV
|
0.000x |
|
Sound Point Meridian Capital, Inc.
PINK:SPMCP
|
N/A |
|
SmartSet Automation LLC
PINK:SLDC
|
0.002x |
Annual Cash Flow Conversion Efficiency for Waverley Pharma Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Waverley Pharma Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$-2.03 Million | CA$-410.19K | 0.202x | -77.52% |
| 2023-12-31 | CA$-1.14 Million | CA$-1.02 Million | 0.898x | +513.44% |
| 2022-12-31 | CA$1.09 Million | CA$-237.06K | -0.217x | +51.33% |
| 2021-12-31 | CA$1.79 Million | CA$-798.78K | -0.446x | -152.15% |
| 2020-12-31 | CA$2.04 Million | CA$-361.70K | -0.177x | +64.34% |
| 2019-12-31 | CA$2.85 Million | CA$-1.41 Million | -0.497x | -35.82% |
| 2018-12-31 | CA$3.97 Million | CA$-1.45 Million | -0.366x | -1600.85% |
| 2017-12-31 | CA$5.06 Million | CA$-108.69K | -0.021x | -100.23% |
| 2016-12-31 | CA$-11.62K | CA$-108.69K | 9.350x | -9.27% |
| 2015-12-31 | CA$-10.55K | CA$-108.69K | 10.306x | -- |